ImmunityBio (IBRX) Expected to Announce Earnings on Tuesday

ImmunityBio (NASDAQ:IBRX) is anticipated to post its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect ImmunityBio to announce earnings of ($0.07) per share and revenue of $59.23 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million during the quarter, compared to analysts’ expectations of $49.70 million. On average, analysts expect ImmunityBio to post ($0.30) EPS for the current fiscal year and ($0.11) EPS for the next fiscal year.

ImmunityBio Trading Down 5.0%

IBRX opened at $7.81 on Tuesday. The company has a market cap of $8.28 billion, a P/E ratio of -8.05 and a beta of 0.02. The business’s 50-day moving average price is $8.65 and its 200-day moving average price is $7.73. ImmunityBio has a 12 month low of $1.95 and a 12 month high of $12.43.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on IBRX. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, October 6th. Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price target on shares of ImmunityBio in a research note on Wednesday, October 14th. Jefferies Financial Group lifted their price target on ImmunityBio from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of ImmunityBio in a research report on Thursday, October 15th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Insider Transactions at ImmunityBio

In other news, Director Cheryl Cohen sold 81,056 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $10.50, for a total transaction of $851,088.00. Following the completion of the sale, the director directly owned 100,309 shares in the company, valued at approximately $1,053,244.50. This represents a 44.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry Simon sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $10.75, for a total value of $268,750.00. Following the completion of the sale, the director directly owned 2,777,788 shares in the company, valued at $29,861,221. The trade was a 0.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 66.10% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune response against cancer and infectious diseases. The company’s approach combines immune-system modulators, cellular therapies, vaccines and other technologies intended to address multiple stages of the disease-treatment process.

Its lead product, Anktiva (nogapendekin alfa inbakicept-pmln, also known as N-803), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells.